



*Amendments to the Claims*

The listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) An inhalable, stable formulation comprising methacholine chloride at a concentration of from 0.025 to 25 mg/ml dissolved in a buffer solution having a pH in the range of ~~about 4~~ to ~~about 5~~, wherein said buffer solution is an acetate buffer solution containing less than 0.2% acetate or a citrate buffer solution containing less than 0.1% citrate.

2. (Currently amended) The formulation according to claim 1, wherein the pH of the buffer solution is in the range of ~~about 4.5~~ to ~~about 5.0~~.

3. (Currently amended) The formulation according to claim 1, wherein the pH of the buffer solution is in the range of ~~about 4.5~~ to ~~about 4.7~~.

4. (canceled)

5. (Currently amended) The formulation according to claim ~~[[4]]~~ 1, wherein the acetate buffer solution has an acetate concentration of ~~about 4.5~~ to ~~about 8.5~~ mM.

6. (Currently amended) The formulation according to claim 5, wherein the acetate concentration is ~~about 4.8~~ mM.

7. (Currently amended) The formulation according to ~~claims 1~~ claim 1, which has been filter sterilized by aseptic filtration.

8. (Original) The formulation according to claim 1, which additionally comprises a preservative.

9. (Original) The formulation according to claim 1, which additionally comprises sodium chloride.

10. (Original) The formulation according to claim 1, which is provided in a sealed container.

11. (Original) The formulation according to claim 10, wherein the sealed container comprises a stopper.

12. (Original) The formulation according to claim 1 for use in bronchoprovocation testing.

13-18 (Cancelled).

19. (Original) A packaged pharmaceutical product comprising a formulation according to claim 1 in a sealable container.

20. (Original) The packaged pharmaceutical product according to claim 19, wherein the container is a vial or an ampoule constructed of materials generally accepted for pharmaceutical preparations.

21. (Original) The packaged pharmaceutical product according to claim 20, wherein vial is sealed using a suitable closure system to ensure sterility.

22-26 (Cancelled).